Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review

Abstract Objective  Palivizumab is a humanized monoclonal antibody approved for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease. This systematic review summarized evidence on the effectiveness and safety of palivizumab when used in approved populations. Study Design  A systematic review of Phase III trials and observational studies was conducted according to the population, intervention, comparator, outcome, timing, setting (PICOTS) approach (PROSPERO, CRD42021281380). Target populations consisted of infants with a history of premature birth (≤35-week gestational age) and children aged <2 years with bronchopulmonary dysplasia (BPD) or with hemodynamically significant congenital heart disease (hs-CHD). Outcomes of interest included RSV-related hospitalization, admission to intensive care unit (ICU), requirement for mechanical ventilation, treatment-related adverse events (AEs), and RSV-related deaths. Information sources were literature search (Ovid MEDLINE and Embase), pragmatic searches, and snowballing (covering the period up to 07 September 2021). Results  A total of 60 sources were included (5 Phase III trials and 55 observational studies). RSV-related hospitalization rates following palivizumab prophylaxis in Phase III trials were 1.8% in premature infants and 7.9% in children with BPD, which were significantly lower than rates in placebo arms. In the real-world setting, similar hospitalization rates were found (0.7–4.0% in premature infants [16 studies] and 0–5.5% in patients with BPD [10 studies]) with ICU admission reported in 0 to 33.3% of patients hospitalized for RSV. In Phase III trials, RSV-related mortality rates were 0.2 and 0.3%, while AEs occurred in 11% of premature and/or BPD patients and 7.2% of hs-CHD patients, consisting mainly of injection site reaction, fever, and diarrhea. Similar results were found in observational studies. Conclusion  This systematic review supports the effectiveness and safety of palivizumab in the indicated populations. Key Points Systematic review supports the positive benefit-risk profile of palivizumab in the indicated populations. Real-world safety and effectiveness of palivizumab are consistent with Phase III trials results. Palivizumab reduces RSV-related hospitalizations, ICU admissions, and need for mechanical ventilation.

[1]  H. Torchin,et al.  Occurrence and severity of acute respiratory infections during the first year among very preterm infants: an Epipage-2 cohort analysis , 2021, European Journal of Pediatrics.

[2]  J. Castilla,et al.  Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children , 2021, Human vaccines & immunotherapeutics.

[3]  Richard Taylor,et al.  Palivizumab Prophylaxis for infants 29 to 32 weeks gestation at birth: A 10-year audit from Vancouver Island using BC Guidelines. , 2020, Paediatrics & child health.

[4]  S. Saffari,et al.  Effectiveness of Palivizumab against Respiratory Syncytial Virus Hospitalization among Preterm Infants in a Setting with Year-round Circulation. , 2020, The Journal of infectious diseases.

[5]  H. Mussaffi,et al.  Palivizumab following extremely premature birth does not affect pulmonary outcomes in adolescents. , 2020, Chest.

[6]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[7]  L. Machado,et al.  Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil , 2019, BMC Pediatrics.

[8]  C. Chung,et al.  Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study , 2019, Pediatric Research.

[9]  L. Bentur,et al.  Long term follow-up of Palivizumab administration in children born at 29-32 weeks of gestation. , 2019, Respiratory medicine.

[10]  J. Claydon,et al.  Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis. , 2019, CMAJ open.

[11]  K. Lanctôt,et al.  Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders , 2019, European Journal of Pediatrics.

[12]  K. Hon,et al.  Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection—A Cost-Effectiveness Analysis , 2018, Journal of tropical pediatrics.

[13]  G. Lenhart,et al.  Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016 , 2018, American Journal of Perinatology.

[14]  S. Chiu,et al.  Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study , 2018, The Journal of pediatrics.

[15]  C. Granato,et al.  Respiratory syncytial virus evaluation among asymptomatic and symptomatic subjects in a university hospital in Sao Paulo, Brazil, in the period of 2009‐2013 , 2018, Influenza and other respiratory viruses.

[16]  I. Janahi,et al.  Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar , 2018, International journal of general medicine.

[17]  D. Brandon,et al.  Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus , 2017, Advances in neonatal care : official journal of the National Association of Neonatal Nurses.

[18]  E. Simões,et al.  Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six‐Year Follow‐up Study , 2017, American journal of respiratory and critical care medicine.

[19]  K. Lanctôt,et al.  Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015) , 2017, The Pediatric infectious disease journal.

[20]  K. Lanctôt,et al.  First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015) , 2017, European Journal of Pediatrics.

[21]  M. Maule,et al.  Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study , 2017, The Pediatric infectious disease journal.

[22]  B. Urlesberger,et al.  Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis , 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[23]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[24]  I. Kang,et al.  Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases , 2016, Korean circulation journal.

[25]  H. Mussaffi,et al.  Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely. , 2016, Chest.

[26]  K. Lanctôt,et al.  Comparing First- and Second-Year Palivizumab Prophylaxis in Patients with Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). , 2015, The Pediatric infectious disease journal.

[27]  Hye Soo Yoo,et al.  Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia , 2015, Journal of Korean medical science.

[28]  K. Lanctôt,et al.  Respiratory Related Hospitalizations In Premature Infants Prophylaxed With Palivizumab In the Canadian Registry of Palivizumab (Caress) , 2015 .

[29]  David M. Smith,et al.  Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis , 2014, BMC Pediatrics.

[30]  H. Jafri,et al.  Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity , 2014, Infectious Diseases and Therapy.

[31]  Eneida A. Mendonça,et al.  Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection , 2014, Pediatrics.

[32]  F. Huang,et al.  A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan , 2014, PloS one.

[33]  B. Paes,et al.  40: Respiratory Illness and Respiratory Syncytial Virus Hospitalizations in the Canadian Registry for Synagis (CARESS) Over Eight Seasons (2005–2013) , 2014 .

[34]  M. Moore,et al.  An Overview of Respiratory Syncytial Virus , 2014, PLoS pathogens.

[35]  Kirsten Shuler,et al.  Critical appraisal tools , 2014 .

[36]  M. Oncel,et al.  Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis , 2013, Iranian journal of pediatrics.

[37]  E. Simões,et al.  Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants , 2013, Pediatrics.

[38]  K. Lanctôt,et al.  Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries , 2013, Clinical & developmental immunology.

[39]  G. Notario,et al.  A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation , 2012, BMC Research Notes.

[40]  J. Mann,et al.  Respiratory Syncytial Virus Morbidity and Outpatient Palivizumab Dosing in South Carolina, 2004–2009 , 2012, Southern medical journal.

[41]  R. Agarwal,et al.  Palivizumab immunoprophylaxis (PIP) for infants with chronic lung disease (CLD) of prematurity – a prospective observational study , 2012, Archives of Disease in Childhood.

[42]  K. Lanctôt,et al.  A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS) , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[43]  Boscoe M. Paes,et al.  Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations , 2011, European Journal of Pediatrics.

[44]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[45]  Seung Gu Chang,et al.  Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009 , 2010, Journal of Korean medical science.

[46]  G. Losonsky,et al.  Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial , 2010, Pediatrics.

[47]  J. Dunn,et al.  Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. , 2010, Journal of managed care pharmacy : JMCP.

[48]  K. Coley,et al.  Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. , 2010, Journal of managed care pharmacy : JMCP.

[49]  Haesoon Lee,et al.  Incidence Of Wheezing In Premature Infants Who Received Synagis (Palivizumab) Prophylaxis: Eleven -Year Follow -up , 2009, ATS 2009.

[50]  E. Simões,et al.  Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. , 2007, The Journal of pediatrics.

[51]  H. Togari,et al.  Results of clinical surveillance during the Japanese first palivizumab season in 2002–2003 , 2006, Pediatrics international : official journal of the Japan Pediatric Society.

[52]  J. Haas,et al.  Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[53]  K.,et al.  Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. , 2003, The Journal of pediatrics.

[54]  J. Quero,et al.  Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants , 2003, The Pediatric infectious disease journal.

[55]  J. Groothuis.  Safety of Palivizumab in Preterm Infants 29 to 32 Weeks' Gestational Age Without Chronic Lung Disease to Prevent Serious Respiratory Syncytial Virus Infection , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[56]  R. Hirsch,et al.  Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry , 2003, Pediatric pulmonology.

[57]  L. Weisman.  Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions , 2003, The Pediatric infectious disease journal.

[58]  J. Rozé,et al.  Incidence of respiratory syncytial virus‐related hospitalizations in high‐risk children: Follow‐up of a national cohort of infants treated with Palivizumab as RSV prophylaxis , 2002, Pediatric pulmonology.

[59]  K. Lanctôt,et al.  Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes , 2002, The Pediatric infectious disease journal.

[60]  OH PAULI..  Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes , 2002 .

[61]  J. Groothuis.  Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. , 2001, The Pediatric infectious disease journal.

[62]  T. Powers,et al.  Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. , 2000, The Pediatric infectious disease journal.

[63]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.